PsychedelicNewsBreaks Archive - Page 11 of 65

FridayJan 06, 2023 11:35 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the industry. The event is known for gathering together global industry leaders with officials from emerging fast-growth companies along with innovative technology creators and members of the investment community. FSD Pharma director and CEO Dr. Lakshmi…

WednesdayJan 04, 2023 1:48 pm

PsychedelicNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Recaps 2022, Eyes 2023 as ‘Pivotal Year’

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered care, today provided a year-end summary of 2022 accomplishments. “2022 was a busy year of behind-the-scenes activity laying the foundations with Health Canada in preparation for the planned clinical trial application and sourcing the related ibogaine drug supply,” said Nick Karos, chief executive officer and board member of Universal Ibogaine. “We are finalizing discussions with several potential funding partners and intend on closing the second round of our current convertible debt financing very shortly. 2023 will be a pivotal…

TuesdayDec 20, 2022 11:13 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage – within less than 18 months since discovery – which is a remarkable accomplishment and a true testament to the strength of our team,” said Cybin’s Chief Executive Officer Doug Drysdale. “Along with our clinical programs,…

WednesdayDec 07, 2022 11:06 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place Dec. 4-7, 2022, in Phoenix, Arizona. According to the update, the data, including new pharmacokinetics (“PK”) findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder (“MDD”). “These new findings demonstrate the unique PK properties of CYB003 compared with classical psilocybin and further supports our ongoing first-in-human phase 1/2a clinical trial evaluating CYB003 for the treatment…

WednesdayNov 30, 2022 10:59 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the board of directors. Dr. Kotra, an academic entrepreneur, has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He is the recipient of…

MondayNov 21, 2022 12:24 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue, with initial data expected during the first quarter of 2023. “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where…

TuesdayNov 15, 2022 1:25 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug Drysdale. “In addition to our clinical work, we have been actively broadening our robust IP portfolio through securing strategic licensing agreements for preclinical psychedelic-based compounds that will support our ongoing drug development efforts. These recent…

FridayNov 11, 2022 11:55 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. According to the update, the objective of this safety evaluation study, conducted by Experimur (a Frontage Company), is to evaluate the SP-26 compound to establish a maximum tolerated dose. The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by fatigue, sleep problems and memory issues. “Our team is excited about this milestone in our collaboration with our joint venture…

ThursdayNov 10, 2022 1:28 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced progress on its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”). According to the update, dosing has been completed for four out of five participant cohorts, and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The trial was acquired from Entheon Biomedical Corp. in July 2022. “The acquisition of the Phase 1 DMT study was done with an eye toward informing and accelerating the clinical path forward for CYB004, and we are very pleased with the progress so far,”…

ThursdayNov 03, 2022 2:42 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the body. With no cure available, fibromyalgia can be a debilitating condition that extends beyond the pain to cause extreme fatigue, anxiety and memory issues. Silo’s novel ketamine formulation, designated as SP-26, is currently undergoing safety evaluation to treat fibromyalgia,” reads a recent article. “We are…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks